Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Shakes Up R&D Strategy To Cope With US Pricing Pressures

Executive Summary

Increasing competition and pricing pressures in the US, have led Novo Nordisk to halve its profit growth expectations for 2017. In response, the diabetes drug developer plans to double-down on R&D efforts, expand into new therapy areas and seek external deals for early-stage assets to bulk up its pipeline.

Advertisement

Related Content

Is Anemic Growth Sending Novo Nordisk After Global Blood Therapeutics?
Stockwatch: Pfizer, Roche, AZ, Novo Prolong Pharmaceutical Winter
Novo Still Seeking Superior Tresiba Follow-On, Says CSO
Novo Nordisk 'Caught Short' By Lantus Exclusion
Stockwatch: An Earnings Season Renaissance Fades
Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss
1,000 Layoffs Expected At Novo Nordisk As US Pricing Pressures Bite

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097566

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel